HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third-Party Assistance On US FDA’s Plate For Cutting Backlog Of Supplement Facility Inspections

Executive Summary

“We had a good chunk of time when our investigators were not able to go out and get into facilities in a safe manner,” says Cara Welch, acting director of FDA Office of Dietary Supplement Programs. “I absolutely agree on starting the conversation for third-party inspections,” she adds.

You may also be interested in...



Remote Site Visits Will Help US FDA Keep Reviews On Track As Pandemic Constraints Continue

Guidance discusses what are generically called virtual inspections, but which the agency terms “remote interactive evaluations.” As site inspections remain constrained by the pandemic, remote interactive evaluations “should help FDA operate within normal timeframes,” the document says.

Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

Supplement Firm Fails GMP Inspection Four Months After Third-Party Certification

GMP warning to Nutra Solutions USA reflects not only that manufacturers and other supplement firms are responsible to maintain compliance at their facilities, but also third-party inspectors should be responsible for their certifications, say industry stakeholders.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel